Intralenticular ozurdex® - One year later

Kathleen A. Regan, Charles R. Blake, Zachary Lee Lukowski, Siva S.R. Iyer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

Original languageEnglish (US)
Pages (from-to)590-594
Number of pages5
JournalCase Reports in Ophthalmology
Volume8
Issue number3
DOIs
StatePublished - Sep 14 2017
Externally publishedYes

Fingerprint

Macular Edema
Cataract
Crystalline Lens
Phacoemulsification
Cataract Extraction
Optical Coherence Tomography
Foreign Bodies
Dexamethasone
Visual Acuity
Steroids
Observation

Keywords

  • Diabetic macular edema
  • Intralenticular dexamethasone implantation (Ozurdex®)
  • Nuclear sclerotic cataract

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intralenticular ozurdex® - One year later. / Regan, Kathleen A.; Blake, Charles R.; Lukowski, Zachary Lee; Iyer, Siva S.R.

In: Case Reports in Ophthalmology, Vol. 8, No. 3, 14.09.2017, p. 590-594.

Research output: Contribution to journalArticle

Regan, Kathleen A. ; Blake, Charles R. ; Lukowski, Zachary Lee ; Iyer, Siva S.R. / Intralenticular ozurdex® - One year later. In: Case Reports in Ophthalmology. 2017 ; Vol. 8, No. 3. pp. 590-594.
@article{02000abeffe9418499bc8e9ede9ddf74,
title = "Intralenticular ozurdex{\circledR} - One year later",
abstract = "Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex{\circledR}, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.",
keywords = "Diabetic macular edema, Intralenticular dexamethasone implantation (Ozurdex{\circledR}), Nuclear sclerotic cataract",
author = "Regan, {Kathleen A.} and Blake, {Charles R.} and Lukowski, {Zachary Lee} and Iyer, {Siva S.R.}",
year = "2017",
month = "9",
day = "14",
doi = "10.1159/000485318",
language = "English (US)",
volume = "8",
pages = "590--594",
journal = "Case Reports in Ophthalmology",
issn = "1663-2699",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Intralenticular ozurdex® - One year later

AU - Regan, Kathleen A.

AU - Blake, Charles R.

AU - Lukowski, Zachary Lee

AU - Iyer, Siva S.R.

PY - 2017/9/14

Y1 - 2017/9/14

N2 - Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

AB - Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

KW - Diabetic macular edema

KW - Intralenticular dexamethasone implantation (Ozurdex®)

KW - Nuclear sclerotic cataract

UR - http://www.scopus.com/inward/record.url?scp=85038638775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038638775&partnerID=8YFLogxK

U2 - 10.1159/000485318

DO - 10.1159/000485318

M3 - Article

AN - SCOPUS:85038638775

VL - 8

SP - 590

EP - 594

JO - Case Reports in Ophthalmology

JF - Case Reports in Ophthalmology

SN - 1663-2699

IS - 3

ER -